Articles

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin

Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Core Facility – Proteomics, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Department of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno;Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno
Vol. 98 No. 7 (2013): July, 2013 https://doi.org/10.3324/haematol.2012.081620